Sunshine Biopharma (SBFM) said Wednesday that it completed additional studies of its K1.1 mRNA lipid nanoparticle product, which confirmed it as a novel therapeutic agent for liver cancer.
Under repeated dosing, the mRNA product was found to reduce the growth of three different types of human hepatocellular carcinoma tumors in mice, with good tolerability, the company said.
The company said it is now conducting additional studies to define the optimum dosing of truncated version of the product, which is said to offer better efficacy at lower doses.
Sunshine Biopharma shares were 49% higher in recent premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。